Flecainide is named as an intervention in 4 current clinical trials in our France, Belgium, Norway and South Korea registers. 2 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Assistance Publique - Hôpitaux de Paris (1). The most-studied condition is Atrial Fibrillation (AF). The EU clinical trials register (CTIS) separately lists 3 authorised or ongoing trials.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Flecainide. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
AVISO - Assessment of Flecainide versus Bisoprolol as First-Line Treatment for Premature Ventricular Contractions: a Multicenter Randomized Clinical Trial
2025-524584-20-00 · Cardiovascular Diseases
|
Phase 3 | Authorised | Assistance Publique Hopitaux De Paris | France |
|
Randomized Evaluation of fleCAinide safety vs. STandard of care in patients with coronary artery disease and Atrial Fibrillation (ReCAST AF).
2025-525121-13-00 · CTIS ↗ · Cardiovascular Diseases
|
Phase 4 | Ongoing | UZ Leuven | Belgium |
|
Early treatment of Atrial fibrillation for Stroke prevention Trial in acute STROKE (EAST-STROKE)
2025-521260-35-00 · CTIS ↗ · Cardiovascular Diseases
|
Phase 4 | Ongoing | University Medical Center Hamburg-Eppendorf | Spain, Germany, Netherlands |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
5 single-substance products containing Flecainide on the HPRA medicines list.
No entry for Flecainide in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Assistance Publique - Hôpitaux de Paris | 1 |
| Universitaire Ziekenhuizen KU Leuven | 1 |
| Oslo University Hospital | 1 |
| Inha University Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in France | 1 | 0 |
| Clinical trials in Belgium | 1 | 1 |
| Clinical trials in Norway | 1 | 1 |
| Clinical trials in South Korea | 1 | 0 |
| EU register (CTIS) | 3 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
4 current trials in our France, Belgium, Norway and South Korea registers name Flecainide (also registered as C01B C04) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 4 trials are recruiting: 1 with sites in Belgium and 1 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Assistance Publique - Hôpitaux de Paris (1), Universitaire Ziekenhuizen KU Leuven (1), Oslo University Hospital (1) and Inha University Hospital (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 5 single-substance products containing Flecainide, for example Flecainide 100mg Tablets (Teva B.V.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Flecainide has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Flecainide works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Flecainide works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Flecainide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.